Dates of Meeting: September 29–30, 1997.
Time of Meeting: 9:00 a.m.–recess, September 29. 8:30 a.m.–adjournment, September 30.
Place of Meeting: II Rockledge Center, Room 9104, 6701 Rockledge Drive, Bethesda, Maryland 20892.
Agenda: Review and prioritize new research concepts and proposed initiatives developed by the Division of Blood Disease Scientific Research Groups.
Contact Person: Carol H. Letendre, Ph.D., NHLBI/DBDR, II Rockledge Center, 6701 Rockledge Drive, Rm. 10162, MSC 7950, Bethesda, Maryland 20892, (301) 435–0080.
(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)
Dated: August 28, 1997.

LaVeen M. Ponds,

Policy Analyst, NIH CMO.

[FR Doc. 97–23481 Filed 9–3–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Child Health and Human Development Special Emphasis Panel (SEP) meeting:

Name of SEP: Neurodevelopmental Battery for the Maternal Lifestyle Study (Teleconference).
Date: September 3, 1997.
Time: 1:00 p.m. (ET)–adjournment.
Place: 61E Building, Room 5E03, 6100 Executive Boulevard, Rockville, MD 20852.
Contact Person: Hameed A. Khan, Ph.D., 61E Building, Rm. 5E03, Rockville, Maryland 20852, Telephone: 301–496–1485.
Purpose/Agenda: To evaluate and review a contract proposal.
This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The discussions of this proposal could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposal, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.
(Catalog of Federal Domestic Assistance Program Nos. [93.864, Population Research and No. 93.865, Research for Mothers and Children], National Institutes of Health)
Dated: August 27, 1997.

LaVeen M. Ponds,

Policy Analyst, NIH CMO.

[FR Doc. 97–23476 Filed 9–3–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel meeting:

Name of SEP: ZDK1–GRB–6–J2.
Date: November 19, 1997.
Time: 7:30 pm.
Place: Indiana University, School of Medicine, 635 Barnhill Drive, Indianapolis, IN 46202–5120.
Contact Person: Sharee Pepper, Ph.D., Scientific Review Administrator, Review Branch, NIDDK, Natcher Building, Room 6as–25E, National Institutes of Health, Bethesda, Maryland 20892–6600, Phone: (301) 594–7798.
Purpose/Agenda: To review and evaluate grant applications.
This meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
(Catalog of Federal Domestic Assistance Program No. 93.847–849, Diabetes, Endocrine and Metabolic Diseases; Digestive Diseases and Nutrition; and Kidney Diseases, Urology and Hematology Research, National Institutes of Health)
Dated: August 28, 1997.

LaVeen M. Ponds,

Policy Analyst, NIH CMO.

[FR Doc. 97–23480 Filed 9–3–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute on Drug Abuse (NIDA) Special Emphasis Panel meeting:

Purpose/Agenda: To evaluate and review contract proposals.
Name of Committee: NIDA Special Emphasis Panel (Identification and Analysis of THC, Cocaine, and Other Drugs of Abuse and Their Metabolites in Meconium).
Date: September 8, 1997.
Time: 10:00 a.m.
Place: Contracts Management Branch, National Institute on Drug Abuse, NIH, 5600 Fishers Lane, Room 10–49, Rockville, MD 20857, (Telephone Conference).
Contact Person: Mr. Eric Zatman, Contract Review Specialist, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–42, Rockville, MD 20857, Telephone (301) 443–1644.
This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.
The meeting will be closed in accordance with provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
(Catalog of Federal Domestic Assistance Program Numbers: 93.277, Drug Abuse Scientist Development, Research Scientist Development, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs, National Institutes of Health)
Dated: August 28, 1997.

LaVeen M. Ponds,

Policy Analyst, NIH CMO.

[FR Doc. 97–23482 Filed 9–3–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Workshop on Thalidomide: Potential Benefits and Risks

Notice is hereby given of the NIH workshop on ''Thalidomide: Potential Benefits and Risks,'' which will be held September 9–10, 1997, in the Natcher Conference Center of the National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892. The conference begins at 8:30 a.m. on September 9 and at 8 a.m. on September 10.
Thalidomide was associated in 1961 with serious human teratogenicity. Its use in the treatment of morning sickness

and insomnia was abandoned, and it became infamous as an example of a drug with major toxic effects. Thalidomide is now being studied as a treatment for many serious diseases, including erythema nodosum leprosum, chronic graft-versus-host disease, and aphthous ulcers in patients with and without HIV infection.

The purpose of the workshop is to provide a public forum to assess the emerging research opportunities, potential clinical applications, and accompanying risks associated with the use of thalidomide. The meeting is open to researchers, academic and community-based physicians, nurses, pharmacists, other health care professionals, industry personnel, patients, and other interested individuals.

The workshop is sponsored by the Office of Rare Diseases, the Office of Research on Women's Health, the Office of Medical Applications of Research, the National Institute of Allergy and Infectious Diseases, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Institute of Dental Research, and the National Institute of Child Health and Human Development of the National Institutes of Health; by the Center for Drug Evaluation and Research and the Office of Special Health Issues of the Food and Drug Administration; and by the Centers for Disease Control and Prevention.

Advance information on the conference program and conference registration materials may be obtained from Prospect Associates, 1801 Rockville Pike, Suite 500, Rockville, Maryland 20852, (301) 468–MEET; by e-mail to raredisease@PropspectAssoc.com; or at http://rarediseases.info.nih.gov/ord on the World Wide Web.

Dated August 12, 1997.

Ruth L. Kirschstein,

Deputy Director, National Institutes of Health.

[FR Doc. 97–23383 Filed 9–3–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Toxicology Program; Availability of Technical Report on Toxicology and Carcinogenesis Studies of 1-Trans-Delta^9-Tetrahydrocannabinol

The HHS' National Toxicology Program announces the availability of the NTP Technical Report on the toxicology and carcinogenesis studies of 1-trans-delta^9-tetrahydrocannabinol which is a major psychoactive component of marijuana and a widely used Schedule I substance.

Toxicology and carcinogenicity studies were conducted by administering 1-trans-delta^9-tetrahydrocannabinol (THC) in corn oil to groups of 62 vehicle control male rats, 60 low-dose male rats, 70 mid- and high-dose male rats, and 60 female rats at doses of 0, 12.5, 25, or 50 mg THC/kg body weight by gavage for 104 to 105 weeks. Groups of 62 vehicle control male mice, 60 low-dose male mice, 61 mid-dose male mice, and 60 high-dose male mice and 60 female mice were administered 0, 125, 250, or 500 mg THC/kg body weight in corn oil by gavage for 104 to 105 weeks (males) or 105 to 106 weeks (females).

Under the conditions of these 2-year gavage studies, there was no evidence of carcinogenic activity [1] of 1-trans-delta^9-tetrahydrocannabinol in male or female F344/N rats administered 12.5, 25, or 50 mg/kg. There was equivocal evidence of carcinogenic activity of THC in male and female B6C3F1 mice based on the increased incidences of thyroid gland follicular cell adenomas in 125 mg/kg groups.

Increased incidences of thyroid gland follicular cell hyperplasia occurred in male and female mice, and increased incidences of hyperplasia and ulcers of the forestomach were observed in male mice.

The incidences of mammary gland fibroadenomas and uterine stromal polyps were decreased in dosed groups of female rats, as were the incidences of pancreatic adenomas, pituitary gland adenomas, and interstitial cell adenomas of the testis in dosed male rats and liver neoplasms in dosed mice. These decreases were likely related to lower body weights in dosed animals.

Questions or comments about the Technical Report should be directed to Central Data Management at PO Box 12233, Research Triangle Park, NC 27709 or telephone (919) 541–3419.

Copies of Toxicology and Carcinogenesis Studies of 1-Trans-Delta^9-Tetrahydrocannabinol (CAS No. 1972–08–3) (TR–446) are available from Central Data Management, NIEHS, MD E1–02, PO Box 12233, Research Triangle Park, NC 27709; telephone (919) 541–3419.

Dated: August 14, 1997.

Samuel H. Wilson,

NIEHS Deputy Director.

[FR Doc. 97–23381 Filed 9–3–97; 8:45 am]

BILLING CODE 4140–01–M

[1] The NTP uses five categories of evidence of carcinogenic activity observed in each animal study: two categories for positive results (''clear evidence'' and ''some evidence''), one category for uncertain findings (''equivocal evidence''), one category for no observable effect (''no evidence''), and one category for studies that cannot be evaluated because of major flaws (''inadequate study'').

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

Centers for Disease Control and Prevention; Statement of Organization, Functions, and Delegations of Authority

Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772–76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 54 FR 13389–90, dated March 30, 1997) is amended to reflect the transfer of international emergency and refugee functions from the International Health Program Office (IHPO) to the National Center for Environmental Health and the transfer of child survival functions associated with Integrated Case Management activities in IHPO to the National Center for Infectious Diseases.

Section C–B, Organization and Functions, is hereby amended as follows:

Revise the mission and function statement for the *International Health Program Office (CG)* by deleting item (6) and renumbering the remaining items accordingly.

Revise the functional statement for the *Office of the Director (CG1),* by deleting item (7) and renumbering the remaining items accordingly.

Revise the functional statement for the *Division of Field Services (CG6)* by deleting item (5) and renumbering the remaining items accordingly.

Delete in their entirety the title and functional statement for *Child Survival Activity (CG62).*

Revise the functional statement for the *Division of Technical Support (CG7)* by deleting item (6).

Revise the functional statement for the *Epidemiologic Support Branch (CG72)* by deleting items (2) and (8) and renumbering the remaining items accordingly.